Financial reports
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
10-Q
2023 Q1
Quarterly report
28 Apr 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
1 Mar 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
10-Q
2022 Q2
Quarterly report
1 Aug 22
10-Q
2022 Q1
Quarterly report
6 May 22
10-K
2021 FY
Annual report
28 Feb 22
10-Q
2021 Q3
Quarterly report
29 Oct 21
Current reports
8-K
Termination of a Material Definitive Agreement
12 Feb 24
8-K
Other Events
8 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
31 Jan 24
8-K
Other Events
29 Jan 24
8-K
Other Events
24 Jan 24
8-K
Other Events
8 Jan 24
8-K
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHEREĀ® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
30 Nov 23
8-K
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
2 Nov 23
8-K
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
18 Sep 23
8-K
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
31 Jul 23
Registration and prospectus
15-12G
Securities registration termination
22 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Feb 24
Proxies
DEFA14A
Additional proxy soliciting materials
29 Jan 24
DEFA14A
Additional proxy soliciting materials
24 Jan 24
DEFA14A
Additional proxy soliciting materials
8 Jan 24
DEFM14A
Proxy related to merger
2 Jan 24
PREM14A
Preliminary proxy related to merger
21 Dec 23
DEFA14A
Additional proxy soliciting materials
21 Dec 23
DEFA14A
Additional proxy soliciting materials
30 Nov 23
DEFA14A
Additional proxy soliciting materials
30 Nov 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
Other
CT ORDER
Confidential treatment order
30 Apr 20
CT ORDER
Confidential treatment order
6 Dec 19
CT ORDER
Confidential treatment order
6 Dec 19
CT ORDER
Confidential treatment order
19 Mar 19
CT ORDER
Confidential treatment order
19 Mar 19
CT ORDER
Confidential treatment order
25 Sep 18
CT ORDER
Confidential treatment order
11 Jun 18
CT ORDER
Confidential treatment order
23 May 18
CT ORDER
Confidential treatment order
22 Feb 18
CT ORDER
Confidential treatment order
13 Dec 17
Ownership
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
DEAN J MITCHELL
12 Feb 24
4
Kristine Peterson
12 Feb 24
4
Helen M. Thackray
12 Feb 24
4
Mark J Enyedy
12 Feb 24
4
Richard John Wallace
12 Feb 24
4
Stacy Ann Coen
12 Feb 24
4
Renee Lentini
12 Feb 24